Standard BioTools (LAB) Earnings Date & Reports

Key Takeaways

• Standard BioTools is expected to report third quarter 2026 results in early November, with consensus estimates pointing to revenue near $18.8 million and a loss of roughly $0.02 per share.
• The report arrives as the company works toward closing its all-stock combination with privately held Treeline Biosciences, targeted to complete before year-end 2026.
• Full-year 2026 revenue guidance of $80 million to $85 million remains the key benchmark investors will measure against.
• In the prior quarter, revenue of $20.1 million missed consensus and the company posted a net loss of $0.07 per share, weighed down by one-time transaction costs.
• Capital-constrained academic customers and softer instrument sales continue to pressure the legacy mass cytometry and microfluidics business.
• For more on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast.
• Discover Trending AI Robots to see how automated trading strategies are navigating the current market.

Earnings Context and Why It Matters

Standard BioTools is at a pivotal moment. After divesting its SomaScan proteomics business to Illumina in January 2026, the company now reports on a streamlined "continuing operations" base built around mass cytometry and microfluidics. Meanwhile, it has agreed to combine with oncology-focused Treeline Biosciences in a reverse recapitalization intended to redirect the balance sheet toward drug development. This quarterly earnings release therefore serves a dual purpose: it tests whether the remaining tools business can stabilize revenue, and it frames the financial picture heading into a stockholder vote on the merger. For investors, the print is less about a single quarter and more about execution momentum and cash preservation ahead of a transformational close.

Earnings Expectations

Wall Street consensus for the third quarter of 2026 calls for revenue of approximately $18.8 million and a net loss of about $0.02 per share. Those figures compare against second quarter 2026 results, when revenue came in at $20.1 million, down 7.6% year over year, and the company posted a net loss of $0.07 per share on generally accepted accounting principles (GAAP) basis, missing consensus partly due to $14.7 million in transaction costs tied to the Treeline merger.

Management has maintained full-year 2026 revenue guidance of $80 million to $85 million. Key metrics to watch include consumables revenue, which declined 10% year over year last quarter against strong prior-year comparisons, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), which improved 84% year over year to a loss of $2.5 million. Investors will also monitor the company's cash and investments, reported at roughly $541 million at the end of the second quarter, given its importance to the pending transaction.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters spanning industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion for earnings-season research across sectors. Explore the AI Screener to build watchlists and identify setups that align with your own analytical process.

Market Reaction and Investor Sentiment

Sentiment heading into the print remains cautious. The stock has traded well below its 52-week high, and Standard BioTools received a Nasdaq notice in April 2026 indicating its share price had fallen below the $1.00 minimum bid requirement, giving the company a defined window to regain compliance. That backdrop makes quarterly results and merger-related updates a potential source of volatility.

Historically, the shares have shown outsized reactions around earnings, with recent quarters marked by meaningful revenue and EPS (earnings per share) surprises in both directions. Investors appear focused less on near-term profitability and more on the credibility of the Treeline transaction, the pace of cash burn, and whether the legacy tools business can hold revenue near current levels. Any commentary on the merger timeline, stockholder vote, or Nasdaq compliance strategy is likely to carry as much weight as the headline numbers.

Forward Outlook and Key Factors to Monitor

The most important catalyst after this report is the completion of the Treeline Biosciences combination, which management expects to close before year-end 2026, pending stockholder approval. Updates on the vote timing, regulatory steps, and the combined company's capital position will likely dominate investor attention.

On the operating side, watch whether consumables demand stabilizes after last quarter's 10% decline and whether instrument sales recover in still capital-constrained academic and research end-markets. The company's ability to keep adjusted EBITDA losses narrowing while funding restructuring will be a key test of execution discipline.

Finally, the Nasdaq minimum bid price situation remains a live risk. Regaining compliance, whether through sustained price improvement or other measures, is a threshold issue for the listing itself. Investors should also track any updates to the $80 million to $85 million full-year revenue range, which would signal whether demand trends are meeting management's expectations as the merger approaches.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations